IDO+ DCs and Signalling Pathways

被引:18
作者
Wang, Yue [1 ,2 ]
Yang, Bao-Hong [1 ,2 ]
Li, Hui [1 ,2 ]
Cao, Shui [3 ]
Ren, Xiu-Bao [3 ]
Yu, Jin-Pu [1 ,2 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Dept Immunol, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China
[2] Tianjin Med Univ, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin 300060, Peoples R China
[3] Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Tianjin 300060, Peoples R China
基金
中国国家自然科学基金;
关键词
Cancer; dendritic cells; immune response; indoleamine 2,3-dioxygenase; signalling pathways; tolerance; REGULATORY T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE IDO; PLASMACYTOID DENDRITIC CELLS; KAPPA-B PATHWAY; CUTTING EDGE; TGF-BETA; CONSTITUTIVE ACTIVATION; TRYPTOPHAN CATABOLISM; CANCER SUPPRESSION; PERIPHERAL-BLOOD;
D O I
10.2174/15680096113139990073
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dendritic cells (DCs) have traditionally been viewed as constituting an 'information management' system that functions solely to integrate a diverse array of incoming signals, in order to induce immune reactivity. In recent years, however, there has been a shift towards viewing these cells as key regulators in the orchestration of immunological tolerance, with increasing recognition that they are capable of suppressing T-cell responses depending on signalling processes and localised biochemical conditions. Indoleamine 2,3-dioxygenase (IDO) competent (IDO+) DCs are a subset of human DCs which are programmed to a tolerogenic state and play a vital role in establishing and maintaining a tumour-suppressing milieu. The expression of IDO in these DCs represents a key mechanism responsible for inducing the tolerogenic state. However, the mechanisms by which IDO becomes dysregulated in this subset of DCs have not yet been described. In this review, the function of IDO+ DCs within the cancer-tolerogenic milieu, as well as the signals responsible for expression of IDO in this subset, will be discussed.
引用
收藏
页码:278 / 288
页数:11
相关论文
共 50 条
  • [31] Molecular signalling pathways in canine gliomas
    Boudreau, C. E.
    York, D.
    Higgins, R. J.
    LeCouteur, R. A.
    Dickinson, P. J.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2017, 15 (01) : 133 - 150
  • [32] MAP kinase signalling pathways in cancer
    A S Dhillon
    S Hagan
    O Rath
    W Kolch
    Oncogene, 2007, 26 : 3279 - 3290
  • [33] INTERCELLULAR INDUCTION OF APOPTOSIS SIGNALLING PATHWAYS
    Abdelrazzak, Abdelrazek B.
    O'Neill, Peter
    Hill, Mark A.
    RADIATION PROTECTION DOSIMETRY, 2011, 143 (2-4) : 289 - 293
  • [34] IDO-Competent-DCs Induced by IFN-γ Attenuate Acute Rejection in rat Liver Transplantation
    Sun, Xing
    Gong, Zi-jun
    Wang, Zhao-wen
    Li, Tao
    Zhang, Jin-yan
    Sun, Hong-cheng
    Liu, Shuang
    Huang, Li
    Huang, Chen
    Peng, Zhi-hai
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 (04) : 837 - 847
  • [35] Role of the Dietary Phytochemical Curcumin in Targeting Cancer Cell Signalling Pathways
    Mishra, Abhay Prakash
    Swetanshu, Pratichi
    Singh, Pratichi
    Yadav, Shikha
    Nigam, Manisha
    Seidel, Veronique
    Rodrigues, Celia Fortuna
    PLANTS-BASEL, 2023, 12 (09):
  • [36] Developmental signalling pathways in lung cancer
    Daniel, VC
    Peacock, CD
    Watkins, DN
    RESPIROLOGY, 2006, 11 (03) : 234 - 240
  • [37] Ginsenoside-Rg1 acts as an IDO1 inhibitor, protects against liver fibrosis via alleviating IDO1-mediated the inhibition of DCs maturation
    Mo, Chan
    Xie, Shuwen
    Zeng, Ting
    Lai, Yuqi
    Huang, Sha
    Zhou, Chuying
    Yan, Weixin
    Huang, Shaohui
    Gao, Lei
    Lv, Zhiping
    PHYTOMEDICINE, 2021, 84
  • [38] Suppression of survival signalling pathways by the phosphatase PHLPP
    O'Neill, Audrey K.
    Niederst, Matthew J.
    Newton, Alexandra C.
    FEBS JOURNAL, 2013, 280 (02) : 572 - 583
  • [39] Diabetic nephropathy: prevalence, pathogenesis and signalling pathways
    Chintala, Swetha Bindu
    Ganta, Suhasin
    CURRENT SCIENCE, 2023, 124 (08): : 899 - 909
  • [40] Notch Signalling Pathways and Their Importance in the Treatment of Cancers
    Teoh, Seong Lin
    Das, Srijit
    CURRENT DRUG TARGETS, 2018, 19 (02) : 128 - 143